MedTrace Logo

A Trial of SHR-2173 in Healthy Volunteers

NCT07390747 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-03-13

No results posted yet for this study

Summary

The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of SHR-2173 in healthy participants

Conditions

Interventions

DRUG

SHR-2173 Injection/SHR-2173 placebo

Single dose SHR-2173 injection or matching placebo given subcutaneously

Sponsors & Collaborators

  • Atridia Pty Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-06
Primary Completion
2026-08-30
Completion
2026-08-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07390747 on ClinicalTrials.gov